ACROBiosystems Hits Record High, Up 14.83% to RMB 114
On September 18, 2026, ACROBiosystems shares reached a record high, rising 14.83% to RMB 114.00 by 9:36 a. m. , with turnover of RMB 520 million and a total market capitalization of RMB 19.115 billion. First-half 2026 revenue rose 28.97% to RMB 500 million, while net profit increased 17.36% to RMB 98.3562 million. Margin financing balance stood at RMB 229 million as of September 17.
On September 18, 2026, ACROBiosystems shares hit a record high. As of 9:36 a. m. , the stock was up 14.83% at RMB 114.00, with trading volume of 4.7454 million shares, turnover of RMB 520 million, and a turnover rate of 3.74%. The company's total A-share market capitalization reached RMB 19.115 billion, while its free-float A-share market capitalization stood at RMB 14.459 billion. The pharmaceutical and biotechnology sector to which ACROBiosystems belongs rose 1.64% over the same period. Within the sector, 491 stocks advanced, with four hitting the daily limit, including Ruikang Pharmaceutical and Nanhua Bio; 10 stocks declined, with Nanwei shares, Kanghui shares, and Jianerkang among the biggest losers, falling 4.53%, 3.58%, and 1.72%, respectively.
Margin trading data showed that as of September 17, 2026, ACROBiosystems' margin financing and securities lending balance was RMB 229 million, of which the financing balance was RMB 228 million, an increase of RMB 13.8716 million over the past 10 days, or 6.47% month on month. The company's semi-annual report showed that in the first half of 2026, it recorded operating revenue of RMB 500 million, up 28.97% year on year; net profit of RMB 98.3562 million, up 17.36% year on year; basic earnings per share of RMB 0.5883; and a weighted average return on equity of 3.63%.